Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2340852rdf:typepubmed:Citationlld:pubmed
pubmed-article:2340852lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:2340852lifeskim:mentionsumls-concept:C0341697lld:lifeskim
pubmed-article:2340852lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:2340852lifeskim:mentionsumls-concept:C0524474lld:lifeskim
pubmed-article:2340852pubmed:issue3lld:pubmed
pubmed-article:2340852pubmed:dateCreated1990-6-27lld:pubmed
pubmed-article:2340852pubmed:abstractTextAcetyl-L-carnitine 1.5 g and 3.0 g was administered as three divided doses on each of two occasions to 24 people with varying renal failure (creatinine clearance 127-8 ml.min-1). Plasma and urinary concentrations of total-L-carnitine, free (non-esterified) carnitine, short-chain esters and acetyl-L-carnitine were measured. The baseline (pre-study) concentrations of all four substances were related to renal function. Patients whose creatinine clearance was below about 30-40 ml.min-1 were had the highest concentrations. Renal elimination of all four substances was related to dose and to renal function. There was evidence for dose-related elimination, with greater elimination of the larger dose.lld:pubmed
pubmed-article:2340852pubmed:languageenglld:pubmed
pubmed-article:2340852pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2340852pubmed:citationSubsetIMlld:pubmed
pubmed-article:2340852pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2340852pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2340852pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2340852pubmed:statusMEDLINElld:pubmed
pubmed-article:2340852pubmed:issn0031-6970lld:pubmed
pubmed-article:2340852pubmed:authorpubmed-author:KellyJ GJGlld:pubmed
pubmed-article:2340852pubmed:authorpubmed-author:DoyleG DGDlld:pubmed
pubmed-article:2340852pubmed:authorpubmed-author:HuntSSlld:pubmed
pubmed-article:2340852pubmed:authorpubmed-author:MarzoAAlld:pubmed
pubmed-article:2340852pubmed:authorpubmed-author:CarmodyMMlld:pubmed
pubmed-article:2340852pubmed:authorpubmed-author:Arrigoni...lld:pubmed
pubmed-article:2340852pubmed:authorpubmed-author:LaherM SMSlld:pubmed
pubmed-article:2340852pubmed:issnTypePrintlld:pubmed
pubmed-article:2340852pubmed:volume38lld:pubmed
pubmed-article:2340852pubmed:ownerNLMlld:pubmed
pubmed-article:2340852pubmed:authorsCompleteYlld:pubmed
pubmed-article:2340852pubmed:pagination309-12lld:pubmed
pubmed-article:2340852pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:2340852pubmed:meshHeadingpubmed-meshheading:2340852-...lld:pubmed
pubmed-article:2340852pubmed:meshHeadingpubmed-meshheading:2340852-...lld:pubmed
pubmed-article:2340852pubmed:meshHeadingpubmed-meshheading:2340852-...lld:pubmed
pubmed-article:2340852pubmed:meshHeadingpubmed-meshheading:2340852-...lld:pubmed
pubmed-article:2340852pubmed:meshHeadingpubmed-meshheading:2340852-...lld:pubmed
pubmed-article:2340852pubmed:meshHeadingpubmed-meshheading:2340852-...lld:pubmed
pubmed-article:2340852pubmed:meshHeadingpubmed-meshheading:2340852-...lld:pubmed
pubmed-article:2340852pubmed:meshHeadingpubmed-meshheading:2340852-...lld:pubmed
pubmed-article:2340852pubmed:meshHeadingpubmed-meshheading:2340852-...lld:pubmed
pubmed-article:2340852pubmed:meshHeadingpubmed-meshheading:2340852-...lld:pubmed
pubmed-article:2340852pubmed:meshHeadingpubmed-meshheading:2340852-...lld:pubmed
pubmed-article:2340852pubmed:year1990lld:pubmed
pubmed-article:2340852pubmed:articleTitlePharmacokinetics of oral acetyl-L-carnitine in renal impairment.lld:pubmed
pubmed-article:2340852pubmed:affiliationInstitute of Biopharmaceutics, Athlone, Ireland.lld:pubmed
pubmed-article:2340852pubmed:publicationTypeJournal Articlelld:pubmed